The Evolving Healthcare System in China Driven by Evidence-Based Decision-Making

New policies and regulations are being developed better to meet the health needs of over a billion people in China. The demand for scientific evidence has increased dramatically, and this requires accurate evaluation of innovations. In this context, health economics and outcomes research (HEOR) is instrumental to evidence-based decision-making and plays a significant role in China’s healthcare reform.
Leveraging real-world evidence and AI technology, HLT provides turnkey solutions to help clients gain entrance to the National Reimbursement Drug List and achieve optimal market access in China. Our services include (but are not limited to) developing value propositions and market access strategies, conducting economic models, generating reimbursement submission packages, and developing innovative pricing and reimbursement strategies.

What we do

Pricing & Access Strategy

Medical Insurance Policy Analysis

Pricing Research for New Product

Pricing & Access Strategy

Value Proposition

Value Dossier

Innovative Payment Module Design

Health Economics & Outcome Research

Disease Burden

Current Treatment and Unmet Needs

Quality of Life

Outcomes Research ( meta analysis /
comparative effectiveness analysis)

Healthcare Resource Utilization and Cost

Budget Impact Model

Cost Effectiveness Analysis/ Cost Utility Analysis

Contact us